Weed (BUDZ) Non Operating Income (2010 - 2025)
Weed's (BUDZ) quarterly Non Operating Income came in at -$5718.0 in Q1 2025, down 80.78% year-on-year from -$29746.8 in Q1 2024, and down 80.78% quarter-over-quarter from -$3163.0 in Q1 2024.
Weed (BUDZ) Non Operating Income (2010 - 2025) Analysis & Trends
Weed's Non Operating Income history runs 5 years deep, the most recent figure standing at -$5718.0 for Q1 2025.
- On a quarterly basis, Non Operating Income fell 80.78% year-over-year to -$5718.0 in Q1 2025; TTM through Mar 2025 was -$3645.0, a 406.05% decrease from a year earlier, with the FY2024 full-year figure at -$50325.0, down 106.8% from the prior year.
- Non Operating Income slipped to -$5718.0 in Q1 2025 per BUDZ's latest filing, from -$3163.0 in the prior quarter.
- Across five years, Non Operating Income topped out at -$3163.0 in Q1 2024 and bottomed at -$5718.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Weed | 3.72 Mn | 3.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -5,718.00 |
| Mar 31, 2024 | -3,163.00 |
| Mar 31, 2012 | -882.00 |
| Dec 31, 2011 | 6,118.00 |
| Sep 30, 2011 | -882.00 |
| Jun 30, 2011 | -873.00 |
| Mar 31, 2011 | -863.00 |
| Dec 31, 2010 | 6,118.00 |
| Sep 30, 2010 | -882.00 |